News | Stroke | February 16, 2023

Percent Insular Ribbon Infarction for Growth Rate Prediction, Outcomes in Large-Vessel Occlusive Stroke

Acute ischemic stroke patients with each PIRI score on 5-point scale

February 16, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), percent insular ribbon infarction (PIRI) complements current stroke outcome predictors, classifying patients with slowly progressive stroke who could benefit from late-window endovascular thrombectomy (EVT).

Noting that PIRI was independently associated with infarct growth rate and 90-day outcome, “PIRI may help identify patients who could benefit from late-window EVT when requiring transfer to EVT-capable centers,” wrote head researcher Robert W. Regenhardt, MD, PhD, from the department of neurology at Massachusetts General Hospital and Harvard Medical School.

Analyzing a previous clinical trial of acute stroke patients untreated with reperfusion therapies from January 2007 to June 2009, Regenhardt et al. reevaluated 31 trial patients (median age, 71 years; 12 female, 19 male) with anterior-circulation large-vessel occlusion who underwent serial MRI examinations. Two neuroradiologists independently scored PIRI on presentation MRI—mild (0-1), moderate (2), severe (3-4)—based upon length ratios of the insula portion showing restricted diffusion to the insula’s total length. A 90-day modified Rankin Scale (mRS) was also obtained.

Ultimately, in multivariable models controlling for age, large-vessel occlusion location, and collateral pattern, PIRI category was a significant independent predictor of presentation-to-48-hour infarct growth rate (β=1.3) and 90-day mRS ≤2 (OR=0.2). Sensitivity and specificity for predicting 90-day mRS ≤2 were 90% and 84% for mild-to-moderate PIRI, versus 70% and 74% for symmetric collateral pattern.

“To our knowledge,” the authors of this AJR accepted manuscript added, “the present study is the first to show the PIRI category to be an independent predictor of 90-day mRS <2 in multivariable models.”

For more information: www.arrs.org


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now